Regen BioPharma マネジメント

マネジメント基準チェック /24

現在、CEO に関する十分な情報がありません。

主要情報

David Koos

最高経営責任者

US$10.1k

報酬総額

CEO給与比率	100.0%
CEO在任期間	3.7yrs
CEOの所有権	0.009%
経営陣の平均在職期間	データなし
取締役会の平均在任期間	9.3yrs

経営陣の近況

Recent updates

CEO報酬分析

Regen BioPharma の収益と比較して、David Koos の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Sep 30 2024	n/a	n/a	-US$867k
Jun 30 2024	n/a	n/a	-US$883k
Mar 31 2024	n/a	n/a	-US$840k
Dec 31 2023	n/a	n/a	-US$775k
Sep 30 2023	US$10k	US$10k	US$1m
Jun 30 2023	n/a	n/a	US$1m
Mar 31 2023	n/a	n/a	US$62m
Dec 31 2022	n/a	n/a	US$1m
Sep 30 2022	n/a	n/a	US$2m
Jun 30 2022	n/a	n/a	US$910k
Mar 31 2022	n/a	n/a	-US$67m
Dec 31 2021	n/a	n/a	-US$6m
Sep 30 2021	US$1	n/a	-US$7m
Jun 30 2021	n/a	n/a	-US$4m
Mar 31 2021	n/a	n/a	US$6m
Dec 31 2020	n/a	n/a	US$2m
Sep 30 2020	n/a	n/a	US$3m
Jun 30 2020	n/a	n/a	US$4m
Mar 31 2020	n/a	n/a	-US$4m
Dec 31 2019	n/a	n/a	-US$454k
Sep 30 2019	US$54k	US$54k	-US$3m
Jun 30 2019	n/a	n/a	-US$5m
Mar 31 2019	n/a	n/a	-US$887k
Dec 31 2018	n/a	n/a	-US$2m
Sep 30 2018	US$180k	US$180k	-US$5m

報酬と市場: Davidの総報酬 ($USD 10.05K ) は、 US市場 ($USD 652.28K ) の同様の規模の企業の平均を下回っています。

報酬と収益: Davidの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

David Koos (63 yo)

3.7yrs

在職期間

US$10,050

報酬

Dr. David Raymond Koos, Ph D., DBA., served as Chairman of the Board of Directors, Chief Executive Officer, President, Secretary and Treasurer at SYBLEU INC. Dr. Koos serves as Chairman, CEO, President, Se...

取締役

名称	ポジション	在職期間	報酬	所有権
David Koos	Chairman	3.7yrs	US$10.05k	0.0095% $ 99.6
Amit Patel	Member of Scientific Advisory Board	10.1yrs	データなし	データなし
Ravinder Reddy	Member of Scientific Advisory Board	1.9yrs	データなし	データなし
Weiping Min	Member of Scientific Advisory Board	12.5yrs	データなし	データなし
David Suhy	Member of Scientific Advisory Board	11.2yrs	データなし	データなし
Santosh Kesari	Member of Scientific Advisory Board	9.3yrs	データなし	データなし
Hinrich Gronemeyer	Member of Scientific Advisory Board	9.4yrs	データなし	データなし
William Blaner	Member of Scientific Advisory Board	9.4yrs	データなし	データなし
Rohit Duggal	Member of Scientific Advisory Board	9.3yrs	データなし	データなし
Jonathan Baell	Member of Scientific Advisory Board	9.3yrs	データなし	データなし
Stefano Bertuzzi	Member of Scientific Advisory Board	9.1yrs	データなし	データなし
Mohammad Haris	Member of Scientific Advisory Board	1.9yrs	データなし	データなし

9.3yrs

平均在職期間

経験豊富なボード: RGBPの取締役会は経験豊富であると考えられます ( 9.3年の平均在任期間)。

Regen BioPharma マネジメント

マネジメント基準チェック /24

主要情報

経営陣の近況

Regen BioPharma, Inc. Announces Board Appointments

Recent updates

Regen BioPharma, Inc. has filed a Follow-on Equity Offering in the amount of $2 million.

Regen BioPharma, Inc. has filed a Follow-on Equity Offering in the amount of $2 million.

Regen Biopharma, Inc. Files Provisional Patent Application for Accelerating Hematopoietic Reconstitution After an Insult or Chronic Pathology by Administration of Stem Cell Derived Endothelial Progenitor Cells or Endothelial Cells

Regen BioPharma, Inc. Outlines Future Steps in CAR T Program

Regen BioPharma, Inc Receives Second Phase Confirmatory Data on its Duracar CAR-T Cell Therapy Program

Regen Biopharma, Inc. Expects Second Phase of Confirmatory Study Shortly

Studies on Regen Biopharma, Inc.'s Duracar Indicate Potential Suppression of Autoimmunity, Company Retains Contract Research Organization to Conduct Additional Confirmatory Studies

Regen BioPharma, Inc. Announces Board Appointments

Regen BioPharma, Inc. Develops a Non-Exhaustible CAR-T Cell Therapeutic

Regen BioPharma, Inc. Files Provisional Patent on Car-T Cell Capable of Attracting and Educating Naïve T Cells to Kill Cancer

Regen BioPharma, Inc. Files Patent on Paradigm Shifting RNA/DNA-Based Approach to Cancer Immunotherapy

Regen BioPharma, Inc. Begins Experiments Validating Its Proprietary CAR-T Cell Therapy

Regen Biopharma Develops Novel Means of Using Car-T Cell Immunotherapy to Attack Solid Tumors

Regen BioPharma, Inc. Develops Novel Dedifferentiation Approach for Increasing Efficacy of CAR-T Cells to Treat Solid Tumors

Regen BioPharma, Inc. Files Provisional Patent Application on Second Generation Survivin mRNA Cancer Immunotherapy Vaccine

Regen BioPharma, Inc. to Initiate Development of its Modified mRNA anti-Cancer Vaccine Technology

Regen Biopharma, Inc. Enters into Settlement Negotiations with the Plaintiff in Order to Resolve This Dispute in Mutually Acceptable Manner

Regen Biopharma, Inc. Executes Consulting Agreement with Biotech Research Group Corporation

CEO報酬分析

CEO（最高経営責任者

在職期間

報酬

取締役

平均在職期間

Regen BioPharma マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Regen BioPharma, Inc. Announces Board Appointments

Recent updates

Regen BioPharma, Inc. has filed a Follow-on Equity Offering in the amount of $2 million.

Regen BioPharma, Inc. has filed a Follow-on Equity Offering in the amount of $2 million.

Regen Biopharma, Inc. Files Provisional Patent Application for Accelerating Hematopoietic Reconstitution After an Insult or Chronic Pathology by Administration of Stem Cell Derived Endothelial Progenitor Cells or Endothelial Cells

Regen BioPharma, Inc. Outlines Future Steps in CAR T Program

Regen BioPharma, Inc Receives Second Phase Confirmatory Data on its Duracar CAR-T Cell Therapy Program

Regen Biopharma, Inc. Expects Second Phase of Confirmatory Study Shortly

Studies on Regen Biopharma, Inc.'s Duracar Indicate Potential Suppression of Autoimmunity, Company Retains Contract Research Organization to Conduct Additional Confirmatory Studies

Regen BioPharma, Inc. Announces Board Appointments

Regen BioPharma, Inc. Develops a Non-Exhaustible CAR-T Cell Therapeutic

Regen BioPharma, Inc. Files Provisional Patent on Car-T Cell Capable of Attracting and Educating Naïve T Cells to Kill Cancer

Regen BioPharma, Inc. Files Patent on Paradigm Shifting RNA/DNA-Based Approach to Cancer Immunotherapy

Regen BioPharma, Inc. Begins Experiments Validating Its Proprietary CAR-T Cell Therapy

Regen Biopharma Develops Novel Means of Using Car-T Cell Immunotherapy to Attack Solid Tumors

Regen BioPharma, Inc. Develops Novel Dedifferentiation Approach for Increasing Efficacy of CAR-T Cells to Treat Solid Tumors

Regen BioPharma, Inc. Files Provisional Patent Application on Second Generation Survivin mRNA Cancer Immunotherapy Vaccine

Regen BioPharma, Inc. to Initiate Development of its Modified mRNA anti-Cancer Vaccine Technology

Regen Biopharma, Inc. Enters into Settlement Negotiations with the Plaintiff in Order to Resolve This Dispute in Mutually Acceptable Manner

Regen Biopharma, Inc. Executes Consulting Agreement with Biotech Research Group Corporation

CEO報酬分析

CEO（最高経営責任者

在職期間

報酬

取締役

平均在職期間

マネジメント基準チェック /24